Archives
- 2018-07
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Ferulenol br Experimental and computation Standard samples
2024-02-21
Experimental and computation Standard samples of artemisinin (1) and artemether (2) were purchased from China National Institutes for Food and Drug Control. Their ECD spectra, at a concentration of 1.0–5.0mg/mL in ethanol, were recorded in a quartz cuvette of 1mm optical path length using a Jasco
-
br AMPK as a druggable target AMPK signaling
2024-02-20
AMPK as a druggable target AMPK signaling has attracted considerable attention within the past decades, owing to the capacity of pharmacological compounds (e.g., 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside [AICAR] and metformin) or natural compounds (e.g., resveratrol) to activate AMPK in
-
br Current therapies for metabolic diseases Inborn errors of
2024-02-20
Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m
-
br Disclosures br Author contributions br Grants This work
2024-02-20
Disclosures Author contributions Grants This work was supported by National Institutes of Health/National Heart, Lung, and Blood Institute MERIT Award R37 HL040696 to J.A.F. Acknowledgments Introduction The AGC kinases, named after the protein A, G and C kinases, are an evolutionaril
-
br Introduction Clinical manifestations of Alzheimer s disea
2024-02-20
Introduction Clinical manifestations of Alzheimer's disease (AD) are mainly characterized by progressive intellectual deterioration, memory impairment, cognitive impairment, and psychiatric symptoms. The pathogenesis of AD remains unclear, mainly containing genetic factors, neurotransmitter disor
-
br Funding br Introduction l Dihydroxyphenylalanine l DOPA i
2024-02-20
Funding Introduction l-3,4-Dihydroxyphenylalanine (l-DOPA) is the gold-standard treatment for the motor symptoms of Parkinson's disease (PD); however, its chronic use induces severe motor complications that eventually limit its long-term efficacy (Bastide et al., 2015). The most disabling side
-
Previous studies have demonstrated ATR inhibition
2024-02-20
Previous studies have demonstrated ATR inhibition is effective for treating cancers combining with chemotherapies in lung adenocarcinoma, gastric cancer, HER2 positive breast cancer and chronic lymphocytic leukemia sr9009 to enhance chemotherapy sensitivity [[16], [17], [18],[20], [21], [22]]. VE-8
-
Somatostatin analogs also bind to
2024-02-20
Somatostatin analogs also bind to somatostatin receptors. It has been reported that octreotide has a high affinity for hSSTR2, moderate affinity for hSSTR3 and hSSTR5, and does not bind to hSSTR1 or hSSTR4 (Ben-Shlomo and Melmed 2008). Compared to octreotide, pasireotide displays 40-, 30-, and 5-fol
-
br Interaction between ASK and TRX Thioredoxins
2024-02-20
Interaction between ASK1 and TRX Thioredoxins are small (∼12kDa) dithiol oxidoreductases ubiquitously expressed in species ranging from plants to archaea and mammals. They perform various biological functions, such as reducing protein disulfide bonds, supplying reducing equivalents to redox MLCK
-
Introduction Cytochrome P CYP aromatase
2024-02-20
Introduction Cytochrome P450 19 (CYP19; aromatase) catalyzes the conversion of androgens to estrogens in a three-reaction sequence, where each step depends on NADPH and O2 [[1], [2], [3]]. The first two steps are accepted to be hydroxylations of the steroid C19 methyl group, whereas the final step
-
br Concluding Remarks and Future Perspectives While postmort
2024-02-19
Concluding Remarks and Future Perspectives While postmortem human dna stain material is relatively sparse and has inherent limitations as discussed above, additional investigations could benefit from analysis of in vitro cellular models to corroborate findings in patient material. Generation of
-
br Translational Considerations Targeting the AHR Pathway Mo
2024-02-19
Translational Considerations Targeting the AHR Pathway Modulating AHR function offers exciting therapeutic potential in host immunity and inflammation. However, the emerging concept of AHR function in a cell type-specific manner, combined with differences between AHR activation in cell culture in
-
br Conflict of interest statement br Acknowledgements We are
2024-02-19
Conflict of interest statement Acknowledgements We are very grateful to Maura Agate for her excellent editorial assistance. The work reported in this article was supported largely by the Italian MIUR. Introduction Atenolol is a selective β1-adrenergic receptor blocker that is orally effec
-
All consecutive patients who were confirmatively diagnosed
2024-02-19
All consecutive patients who were confirmatively diagnosed with MP-PPE and TPE, respectively, between January 2008 and December 2016 at Kyungpook National University Hospital, a tertiary referral hospital in South Korea, an area with an intermediate prevalence of active tuberculosis, were enrolled.
-
In humans the major LOs are subdivided by their
2024-02-19
In humans, the major LOs are subdivided by their positional specificity into 5-(ALOX5), 12-(ALOX12) and 15-LO (ALOX15) (Kuhn et al., 2015). 5-LO is the key enzyme for LT biosynthesis and mainly found in mature cells from myeloid origin, including neutrophil, eosinophil and basophil granulocytes, mon
14937 records 169/996 page Previous Next First page 上5页 166167168169170 下5页 Last page